These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26368744)

  • 21. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
    Jin H; Wei Z
    Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New trends in assessment in anticancer treatments by phase II clinical trials].
    Medioni JR; Rycke YD; Asselain B
    Bull Cancer; 2000 Jul; 87(7-8):551-6. PubMed ID: 10969213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical design in phase II clinical trials and its application in breast cancer.
    Perrone F; Di Maio M; De Maio E; Maione P; Ottaiano A; Pensabene M; Di Lorenzo G; Lombardi AV; Signoriello G; Gallo C
    Lancet Oncol; 2003 May; 4(5):305-11. PubMed ID: 12732168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
    Liu J; Lin Y; Shih WJ
    Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
    Kunzmann K; Kieser M
    Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimation of secondary endpoints in two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
    Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
    BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Rescue Strategy for Handling Unevaluable Patients in Simon's Two Stage Design.
    Belin L; Broët P; De Rycke Y
    PLoS One; 2015; 10(9):e0137586. PubMed ID: 26368810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
    Kocherginsky M; Cohen EE; Karrison T
    J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
    Zhao J; Yu M; Feng XP
    BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research design for patient selection in clinical trials phase II].
    Kramar A; Potvin D; Hill C
    Rev Epidemiol Sante Publique; 1996 Aug; 44(4):364-71. PubMed ID: 8927779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.